Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on June 16, 2017, primarily to report on the presentation of updated clinical data for its Bruton's Tyrosine Kinase (BTK) inhibitor, BGB-3111, at the 14th International Conference on Malignant Lymphoma (14-ICML). This included data from a Phase 1 trial in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), as well as data in Waldenström’s macroglobulinemia. The company also announced initial data on BGB-3111 in combination with obinutuzumab for certain lymphoma types.
Key Highlights
- 1BeOne Medicines (ONC) presented updated clinical data for its BTK inhibitor BGB-3111 at the 14-ICML conference.
- 2Data presented included results from a Phase 1 trial in patients with Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).
- 3Updated data for BGB-3111 in Waldenström’s macroglobulinemia was also presented.
- 4Initial clinical data on BGB-3111 combined with obinutuzumab in CLL, SLL, and follicular lymphoma was announced.
- 5The company filed three press releases as exhibits detailing these clinical updates.
- 6BeOne Medicines is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.